Bioidentical Hormone Replacement Therapy (BHRT) for management of Menopause

Presenter: Laura Dickerson, DNP, APRN, FNP-BC

Objectives

Menopause

- Phases & Symptoms
- Diagnosing & Treating


Bioidentical Hormone Replacement Therapy (BHRT)

- Estradiol, Testosterone, and Progesterone
- Delivery Method
- Risks & Consideration
- Follow-up and Monitoring

What is Menopause?

- The natural cessation of menstrual cycles for 12 consecutive months due to the loss of ovarian follicular activity (menstrual cycle, vaginal bleeding, and/or spotting)
- Age range of 40s 50s, with average
 US age of 51
- Encompasses a women's transitional journey from reproductive years, both physically, emotionally, and spiritually

(Mayo Clinic., 2024) (ACOG., 2024)



Phases of Menopause

- Perimenopause: begins when first signs of menopause begin and last until 1 year after final menstrual period (FMP)
 - Cycles typically get shorter during early perimenopause (more frequent cycles)
 - Cycles typically become farther apart when the body is approaching menopause
- Menopause: The natural cessation of menstrual cycles for 12 consecutive months
- **Postmenopause:** Absence of menstrual cycle for greater than 12 months with no ovulatory activity and marked decline or absence of sex hormones (estrogen and progesterone)

(Mayo Clinic., 2024)

Common Symptoms of Menopause

- Cardinal Symptom = Hot Flashes & Night Sweats (Vasomotor)
- Cardinal Symptom = Vaginal dryness, atrophy, dyspareunia
- Mood changes = irritability, depression, anxiety, poor tolerance to average daily stressors
- Sleep disturbances = difficult falling/staying asleep, waking frequently, nocturia
- Decline in motivation, desire in life, libido, and energy
- Worsening or new onset joint pain and generalized body aches
- New onset weight gain and/or inability to lose weight despite dietary and lifestyle adjustments

Causes of Menopause

- Natural Biological Process due to ovarian aging and decreased hormone production (estrogen and progesterone)
- Surgically induced (i.e., Hysterectomy)
- Medical treatments
 - Chemotherapy
 - SERMs (Tamoxifen)
- Endocrine disrupting agents
 - Herbicides, pesticides, heavy metals, radiation, pathogens, parasites, etc.

(ACOG., 2024) (Biote., 2022) (HHS., 2024)

Long-term Health Considerations

- Osteoporosis-related fractures
- Cardiovascular Disease
- Diabetes Mellitus
- Cognitive Impairment
- Cancer

Diagnosing Menopause

- Clinical Evaluation:
 - Collection of Medical History
 - Cycle throughout all stages of life, including LMP
 - History of endometriosis, fibroids, cancer, etc.
 - Identify any triggers
 - Discuss past/current treatment modalities
 - Birth control history
 - Pregnancy and birth history
 - Current Diet, Exercise, and Sleep patterns

Diagnosing Menopause Cont'd

- Clinical Evaluation:
 - Symptom Assessment with completion of health assessment questionnaire
 - Determine symptom onset (weeks, months, years?)

SYMPTOMS	NONE	MILD	MODERATE	SEVERE	VERY SEVERE
Physical Exhaustion (fatigue, lack of energy, stamina or motivation)					
Sleep Problems (difficulty falling asleep or sleeping through the night)					
Irritability (mood swings, feeling aggressive, angers easily)					
Anxiety (feeling overwhelmed, feeling panicky, or feeling nervous)					
Decline in drive or interest (loss of "zest for life," feeling down or sad)					

Diagnosing Menopause Cont'd

- Laboratory Testing
 - Estradiol (E2) = low or absent
 - Progesterone = low or absent
 - FSH = greater than 23
- Lab testing is NOT confirmatory, must consider the WHOLE clinical picture

Treatment Options

- Hormone Replacement Therapy
 - Bioidentical
 - Synthetic
- Non-Hormonal Options
 - Lifestyle changes
 - Herbal Supplements
- Medications
 - Symptom management (i.e., sleep aids, antidepressants, etc.)

Treatment Options Cont'd


- Diet & Nutrition
 - MORE whole foods, LESS processed foods
 - Think high protein, moderate fat, and minimal carbohydrates
- Exercise
 - Regular physical activity as tolerated to support mood and energy level
 - Optimal goal of 8K-10K steps per day
- Stress Reduction Techniques
 - Prayer
 - Yoga
 - Meditation
 - Breathing exercises

Bioidentical Hormone Replacement Therapy (BHRT)


- Utilizes hormones that are structurally identical to those naturally produced by the human body
- Aims to reduce and/or resolve symptoms associated with hormonal imbalances in both females and males
- Hormones often used are estradiol, progesterone, and testosterone
- Allows for an individualized treatment plan




Positive Effects of Bioidentical Estradiol in Females



Positive Effects of Bioidentical Testosterone in Females



Positive Effects of Bioidentical Progesterone in Females



Potential Side Effects of Bioidentical Estradiol and Testosterone

- Postmenopausal bleeding
- Functional erythropoiesis
- Androgenic effects
- Weight Gain/Water Retention
- Breast tenderness/Swelling
- Mood changes
- Hair Loss/Growth
- Acne

<u>Oral</u>

- First-pass effect can lead to gastrointestinal discomfort, nausea, and liver toxicity
- Poor Absorption → Poor Efficacy
- Requires daily dosing for optimal results
- Buccal or sublingual formulations necessitate three times daily administration due to their short half-life.




- Administered to delicate skin regions, including vaginal and scrotal areas
- Multiple factors affect absorption rate
- Can be applied daily or twice daily
- Blood concentration levels may fluctuate
- Risk of transmission to others; exercisecaution around young children

DELIVERY MATTERS

Injection

- Administration on a weekly or biweekly basis
- Fluctuating response "roller coaster"
- Discomfort at the injection site
- Sensitivity/Intolerance to oil-based suspension
- Elevated risk of erythrocytosis and aromatization
- Potentially increase in platelet aggregation



- Enhanced stability of blood levels over time
- Improved patient adherence
- Discomfort at the insertion site
- Risk of pellet extrusion
- Limitations on activities post-procedure

Risks & Considerations

- Age
- Breast Cancer History
- Seizure History
- Clotting Disorder
- Postmenopausal Breakthrough Bleeding
- Pellet Insertion Procedure
- Cost (No insurance coverage)

Continuous Follow-up & Monitoring

- Pellet Delivery Method (E and T only)
 - Initial Labs
 - 8 weeks post-initial pellet insertion, every 3-6 months thereafter
 - Implantation frequency 12-16 weeks, patient dependent
 - Oral progesterone therapy indicated when uterus is intact
 - Diindolylmethane (DIM) Supplementation
- Topical Compounded Cream (E, T, and P)
 - Initial Labs
 - 10 weeks post-initiation of therapy, every 3-6 months thereafter
 - Routine follow-up as indicated

Thank You

Laura Dickerson, DNP, APRN, FNP-BC

815-708-2808

PRHW@primerevivalbyron.com

www.primerevivalbyron.com



Reference

American College of Obstetricians and Gynecologists. (2024, February). *Perimenopausal bleeding and bleeding after menopause*. ACOG. https://www.acog.org/womens-health/faqs/perimenopausal-bleeding-and-bleeding-after-menopause

Bendis, P. C., Zimmerman, S., Onisiforou, A., Zanos, P., & Georgiou, P. (2024). The impact of estradiol on serotonin, glutamate, and dopamine systems. *Frontiers in Neuroscience*, 18. https://doi.org/10.3389/fnins.2024.1348551

Biote, LLC. (2022) Biote Practitioner.

Manson, J. E., Aragaki, A. K., Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Chlebowski, R. T., Howard, B. V., Thomson, C. A., Margolis, K. L., Lewis, C. E., Stefanick, M. L., Jackson, R. D., Johnson, K. C., Martin, L. W., Shumaker, S. A., Espeland, M. A., & Wactawski-Wende, J. (2017). Menopausal hormone therapy and long-term all-cause and cause-specific mortality. *JAMA*, 318(10), 927. https://doi.org/10.1001/jama.2017.11217

Mayo Foundation for Medical Education and Research. (2024, August 7). *Menopause*. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/menopause/symptoms-causes/syc-20353397

Schierbeck, L. L., Rejnmark, L., Tofteng, C. L., Stilgren, L., Eiken, P., Mosekilde, L., Kober, L., & Jensen, J.-E. B. (2012). Effect of hormone replacement therapy on cardiovascular events in recently Postmenopausal women: Randomized trial. *BMJ*, 345(oct09 2). https://doi.org/10.1136/bmj.e6409

U.S. Department of Health and Human Services (HHS). (2024, July 22). *Endocrine disruptors*. National Institute of Environmental Health Sciences. https://www.niehs.nih.gov/health/topics/agents/endocrine